摘要:
NAD(+) has a central function in linking cellular metabolism to major cell-signaling and gene-regulation pathways. Defects in NAD(+) homeostasis underpin a wide range of diseases, including cancer, metabolic disorders, and aging. Although the beneficial effects of boosting NAD(+) on mitochondrial fitness, metabolism, and lifespan are well established, to date, no therapeutic enhancers of 4 novo NAD(+) biosynthesis have been reported. Herein we report the discovery of 3-[[[5-cyano-1,6-dihydro-6-oxo-4-(2-thieny1)-2-pyrimidinyl]thio]methyl]phenylacetic acid (TES-1025, 22), the first potent and selective inhibitor of human ACMSD (IC50 = 0.013 mu M) that increases NAD(+) levels in cellular systems. The results of physicochemical-property, ADME, and safety profiling, coupled with in vivo target-engagement studies, support the hypothesis that ACMSD inhibition increases de novo NAD(+) biosynthesis and position 22 as a first-class molecule for the evaluation of the therapeutic potential of ACMSD inhibition in treating disorders with perturbed NAV-supply or homeostasis.